Pay in 4 interest-free payments of $5.71 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
A body composition substudy of the Phase 2 diabetes trial, published in The Lancet Diabetes & Endocrinology in 2025, used DXA scans to measure changes in fat and lean mass in 189 participants
2016;14(1):12431 e1
The drug is still years away from regulatory approval, but if cleared, it would eventually be relevant for markets like India, which is home to close to 9 crore adults with type 2 diabetes, according to the International Diabetes Federation
Glucagon Receptor Engagement Energy Expenditure and Hepatic Metabolism Although GLP3 exhibits lower potency at glucagon receptors compared to native glucagon, this component of its triagonist mechanism appears critical for its metabolic effects[8]: Increased energy expenditure through thermogenic activation Enhanced hepatic fatty acid oxidation and reduced hepatic steatosis Modulation of hepatic glucose production during fasted states Promotion of lipolysis in adipose tissue Potential effects on lean mass preservation through metabolic adaptations In vitro studies demonstrated that GLP3 achieves efficacy similar to natural glucagon in stimulating glucose production in hepatocytes, while in adipocytes it surpasses native GIP in inducing lipolysis[9]
A reasonable framework is to get a full baseline panel before you start, then recheck the markers that move
It has a Tmax range of 872 hours and achieves 80% bioavailability when administered subcutaneously
US$ 26.55
US$ 20.17
US$ 23.98
